Publications by authors named "Ashpak Bangi"
Article Synopsis
- This study aimed to assess whether DMX-200, a chemokine receptor antagonist, combined with candesartan, could improve outcomes for hospitalized adults under 65 with moderate to severe COVID-19.
- Conducted in ten hospitals in India, the trial was double-blind and placebo-controlled but was terminated early due to challenges in recruitment, resulting in only 49 participants.
- Preliminary results showed both treatment groups had similar outcomes, with no significant differences in disease progression, ICU admissions, or length of hospital stays, indicating that the intervention may not have had a notable impact.
BACKGROUND: Optimal thromboprophylaxis for hospitalized patients with coronavirus disease 2019 (Covid-19) is uncertain. METHODS: In an open-label, adaptive platform trial, we randomly assigned hospitalized adults with Covid-19 to low-dose low-molecular-weight heparin thromboprophylaxis or intermediate-dose or low-dose plus aspirin. In response to external evidence, the aspirin intervention was discontinued and a therapeutic-dose arm added.
View Article and Find Full Text PDFObjective: To determine whether disrupting the renin angiotensin system with angiotensin receptor blockers will improve clinical outcomes in people with covid-19.
Design: CLARITY was a pragmatic, adaptive, multicentre, phase 3, randomised controlled trial.
Setting: 17 hospital sites in India and Australia.